OpenNashEarnings

Health Care · NYSE: TDOC

Teladoc Health earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 24 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Teladoc Health began rolling out Teladoc One with early launch partners while BetterHelp shifted toward insurance-covered therapy, reaching 3,000+ new therapists in the quarter.

Teladoc Health advanced its Integrated Care offering, implementing Teladoc One, a new comprehensive care model, with early launch partners, and expanding hybrid care and AI-enabled tools. Chronic care enrollment reached 1.344 million, up 15%, even as U.S. Integrated Care members slipped 2% to 100.1 million. At BetterHelp, insurance-covered revenue grew from a small base to $32.1 million as cash-pay users kept declining.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗

Quarters

KPI history

Revenue$605.1M−3.4% y/yQ3 2026
Q4 2024: $640.5M (worked out from the annual figure)Q4 ’24$640.5MQ1 2025: $629.4MQ1 ’25$629.4MQ2 2025: $631.9MQ2 ’25$631.9MQ3 2025: $626.4MQ3 ’25$626.4MQ4 2025: $642.3M (worked out from the annual figure)Q4 ’25$642.3MQ1 2026: $613.8MQ1 ’26$613.8MQ2 2026: $606.9MQ2 ’26$606.9MQ3 2026: $605.1MQ3 ’26$605.1M

Fourth quarter worked out from the annual figure.

Data
Q4 2024$640.5M *
Q1 2025$629.4M
Q2 2025$631.9M
Q3 2025$626.4M
Q4 2025$642.3M *
Q1 2026$613.8M
Q2 2026$606.9M
Q3 2026$605.1M
Diluted EPS (GAAP)-$0.15+46.4% y/yQ3 2026
Q1 2025: -$0.53Q1 ’25-$0.53Q2 2025: -$0.19Q2 ’25-$0.19Q3 2025: -$0.28Q3 ’25-$0.28Q1 2026: -$0.36Q1 ’26-$0.36Q2 2026: -$0.21Q2 ’26-$0.21Q3 2026: -$0.15Q3 ’26-$0.15
Data
Q1 2025-$0.53
Q2 2025-$0.19
Q3 2025-$0.28
Q1 2026-$0.36
Q2 2026-$0.21
Q3 2026-$0.15

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin-4.6%+3.7 pts y/yQ3 2026
Q4 2024: -7.5%Q4 ’24-7.5%Q1 2025: -19.2%Q1 ’25-19.2%Q2 2025: -8.6%Q2 ’25-8.6%Q3 2025: -8.3%Q3 ’25-8.3%Q4 2025: -5.6%Q4 ’25-5.6%Q1 2026: -10.1%Q1 ’26-10.1%Q2 2026: -6.1%Q2 ’26-6.1%Q3 2026: -4.6%Q3 ’26-4.6%
Data
Q4 2024-7.5%
Q1 2025-19.2%
Q2 2025-8.6%
Q3 2025-8.3%
Q4 2025-5.6%
Q1 2026-10.1%
Q2 2026-6.1%
Q3 2026-4.6%
Free cash flow$105.2M+8.5% y/yQ3 2026
Q4 2024: $79.8MQ4 ’24$79.8MQ1 2025: $13.2MQ1 ’25$13.2MQ2 2025: $90.2MQ2 ’25$90.2MQ3 2025: $97.0MQ3 ’25$97.0MQ4 2025: $85.1MQ4 ’25$85.1MQ1 2026: $7.9MQ1 ’26$7.9MQ2 2026: $63.7MQ2 ’26$63.7MQ3 2026: $105.2MQ3 ’26$105.2M
Data
Q4 2024$79.8M
Q1 2025$13.2M
Q2 2025$90.2M
Q3 2025$97.0M
Q4 2025$85.1M
Q1 2026$7.9M
Q2 2026$63.7M
Q3 2026$105.2M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$640.5Md$629.4M$631.9M$626.4M$642.3Md$613.8M$606.9M$605.1M
Operating income-$48.2Md-$120.6M-$54.4M-$52.0M-$36.0Md-$61.8M-$37.1M-$28.1M
Operating margin-7.5%-19.2%-8.6%-8.3%-5.6%-10.1%-6.1%-4.6%
Net income-$48.4Md-$93.0M-$32.7M-$49.5M-$25.1Md-$63.8M-$38.9M-$26.9M
Diluted EPS—-$0.53-$0.19-$0.28—-$0.36-$0.21-$0.15
Operating cash flow$85.9Md$15.9M$91.4Md$99.3Md$87.7Md$9.5M$64.7Md$106.5Md
Capital expenditure$6.1Md$2.7M$1.3Md$2.3Md$2.6Md$1.7M$928.0Kd$1.2Md
Free cash flow$79.8M$13.2M$90.2M$97.0M$85.1M$7.9M$63.7M$105.2M
R&D expense$76.8Md$70.0M$68.8M$67.6M$71.6Md$67.9M$62.9M$65.5M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings